2.95
-0.08 (-2.64%)
| Penutupan Terdahulu | 3.03 |
| Buka | 3.02 |
| Jumlah Dagangan | 642,187 |
| Purata Dagangan (3B) | 823,345 |
| Modal Pasaran | 97,549,512 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.75 |
| Harga / Jualan (P/S) | 35.64 |
| Harga / Buku (P/B) | 2.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 15 May 2026 |
| EPS Cair (TTM) | -1.96 |
| Nisbah Semasa (MRQ) | 0.220 |
| Aliran Tunai Operasi (OCF TTM) | -10.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.23 M |
| Pulangan Atas Aset (ROA TTM) | -191.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | NRX Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.38 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 15.88% |
| % Dimiliki oleh Institusi | 13.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2025 | 37,873 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 45.00 (HC Wainwright & Co., 1,425.42%) | Beli |
| Median | 39.50 (1,238.98%) | |
| Rendah | 34.00 (D. Boral Capital, 1,052.54%) | Beli |
| Purata | 39.50 (1,238.98%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.77 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 09 Mar 2026 | 34.00 (1,052.54%) | Beli | 1.73 |
| HC Wainwright & Co. | 03 Mar 2026 | 45.00 (1,425.42%) | Beli | 1.80 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |